PMC3917539_01
Grade 3 skin toxicity secondary to docetaxel.
1752-1947-8-6-1.jpg
PMC3917539_01_1752-1947-8-6-1.jpg
F1
After cycle 1, the patient developed grade 3 skin toxicity (with a predominance of erythrodysesthesia on the soles of her feet and on the palms and dorsa of her hands), grade 3 arthralgia and myalgia, and grade 2 asthenia (Figure 1).
Improvement of skin toxicity during treatment with nanoparticle albumin-bound paclitaxel.
1752-1947-8-6-2.jpg
PMC3917539_01_1752-1947-8-6-2.jpg
F2
Standard paclitaxel would have required a dose reduction or further delays in treatment (Figure 2).